Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin disposes of $335,983 in common shares

Sandra Calvin, SVP and chief accounting officer, sold 5,375 Travere Therapeutics common shares on Sep. 15, 2026. Sales priced between $62.14 and $63.66 per share. * She exercised employee stock options for 5,375 shares at $20.46 to $27.5. Beneficial ownership ended at 42,353 common shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001882909-26-000004), on September 17, 2026, and is solely responsible for the information contained therein. (C)